US FTC Orders Illumina To Divest Cancer Detection Test Maker Grail
By Diane Bartz WASHINGTON (Reuters) -The U.S. Federal Trade Commission (FTC) on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the U.S. market for cancer tests. Illumina said it would appeal the decision, and will seek expedited consideration from an appeals court. The company said…
